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SuMMAry – We focused on the relationship of 0.5% tetracaine- and 0.4% oxybuprocaine-in-
duced corneal anesthesia in rats, and pentadecapeptide BPC 157 (0.4 µg/eye), along with nitric oxide 
synthase (nOS) inhibitor n(gamma)-nitro-l-arginine methyl ester (l-nAMe) (0.1 mg/eye) and/or 
nOS substrate l-arginine (2 mg/eye), applied in the form of eye drops. We assessed corneal sensitiv-
ity recovery (Cochet-Bonnet esthesiometer), corneal lesion elimination (staining with 10% fluores-
cein) and decrease in tear volume (Schirmer test). BPC 157 administration had a full counteracting 
effect. recovery also occurred in the presence of nOS blockade and nOS substrate application. l-
arginine eventually shortened duration of corneal insensitivity and exerted corneal lesion counterac-
tion (and counteraction of tetracaine-induced decrease of tear volume) only in earlier but not in later 
period. l-nAMe application led to longer duration of corneal insensitivity, increase in corneal lesions 
and decrease in tear volume. When l-nAMe and l-arginine were applied together, they antago-
nized each other’s effect. These distinctions may indicate particular nOS involvement (corneal insen-
sitivity vs. corneal lesion along with tear production), distinctively affected by the administration of 
nO agents. however, additional BPC 157 co-administration would re-establish counteraction over 
topical ophthalmic anesthetic-induced effect, be it in its early or late course. We suggest BPC 157 as 
an antidote to topical ophthalmic anesthetics.
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Introduction
Our study was focused on counteracting corneal 
anesthesia using the stable gastric pentadecapeptide 
BPC 157, n(gamma)-nitro-l-arginine methyl ester 
(l-nAMe) and/or l-arginine in rats1-13. After the 
stable gastric pentadecapeptide BPC 1571-13 has been 
demonstrated to act as a potential antidote to bupiva-
caine cardiotoxicity, thereby interacting with local an-
esthetics14, we focused on the potential counteracting 
effect of the stable gastric pentadecapeptide BPC 157 
and tetracaine as a topical ophthalmic anesthetic ap-
plied onto the eye surface. That counteracting effect 
may be related to the nitric oxide synthase (nOS)1-13, 
as follows from the BPC 157 application with nO 
agents, nOS blocker l-nAMe and nOS substrate 
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l-arginine, administered alone and/or in combination. 
Such a counteracting effect may also have a more gen-
eral significance, providing additional antagonizing 
the oxybuprocaine-induced corneal anesthesia, and 
the corresponding effect of the nO agents, l-nAMe 
and l-arginine, administered alone and/or in combi-
nation.
indicatively, counteraction of bupivacaine arrhyth-
mias14 may be seen as part of the larger beneficial effect 
providing that BPC 157 counteracts various arrhyth-
mias14-19. likewise, with BPC 157 application, coun-
teraction of tetracaine- and oxybuprocaine-induced 
corneal anesthesia may appear along with healing of 
perforating corneal injury and total debridement of 
corneal epithelium, thus maintaining corneal transpar-
ency20,21. BPC 157 counteracts the damaging effects of 
lacrimal gland extirpation and dry eye syndrome in 
rats22. We also revealed nOS dependence of atropine-
induced mydriasis and l-nAMe- and l-arginine-
induced miosis and reversal by the pentadecapeptide 
BPC 157 in both rats and guinea pigs23. This may be 
particularly important considering corneal lesions that 
may be induced by local anesthetic application24-27.
As an original antiulcer peptide, BPC 157 has vir-
tually no known toxicity of its own, the lethal dose 
(ld) value has not yet been established, and there 
were no side effects in clinical trials such as ulcerative 
colitis and multiple sclerosis1-13. Also indicative of spe-
cial relation, BPC 157 caused significant antagonism 
of general anesthesia produced by thiopental with a 
parallel shift of the dose-response curve to the right, 
manipulating in both ways with nOS activity modu-
lation (especially, the potentiating effects of l-nAMe 
were abolished)28. This counteraction was observed, 
along with the evidence that BPC 157 largely interacts 
with nOS in different models and species1-13.
On the other hand, BPC 157 produced analgesia in 
the MgSO4 and acetic acid test in mice, a model of 
prolonged pain associated with tissue injury29. This in-
dicates that BPC 157 may have local anesthetic activ-
ity of its own.
Thus, to counteract tetracaine- and oxybuprocaine-
induced corneal anesthesia, the previously reported ef-
fective dose regimens of the pentadecapeptide BPC 
15714-19, along with nOS inhibitor l-nAMe and 
nOS substrate l-arginine, were administered after 
tetracaine and oxybuprocaine application in rats.
Methods
Animals
Wistar Albino male rats (200 g b.w.) were random-
ly assigned to the experiments (6 animals at least per 
experimental group and interval), all of which were ap-
proved by the local ethics Committee of the School of 
Medicine, university of Zagreb, Zagreb, Croatia (no. 
380-59-10106-19-111/100; 641-01/19-02/01). fur-
thermore, all experiments were carried out under blind 
protocol and the effect was assessed by examiners who 
were completely unaware of the given protocol. The 
research and experiments also followed the ArVO 
Statement for the use of Animals in Ophthalmic and 
Vision research.
Drugs and experimental protocol
Pentadecapeptide BPC 157 (GePPPGKPAd-
dAGlV, M.W. 1419, diagen, ljubljana, Slovenia) 
dissolved in saline was used in all experiments. The 
BPC 157 peptide is part of the sequence of human 
gastric juice BPC protein and is freely soluble in water 
at ph 7.0 and saline. it was prepared as described pre-
viously with 99% high-pressure liquid chromatogra-
phy (hPlC) purity, expressing 1-des-Gly peptide as 
an impurity14-19. At 15 minutes after diazepam (5 mg/
kg intraperitoneally), two drops of 0.5% tetracaine 
(tetrakain 0.5%, Gradska ljekarna, Zagreb, Croatia) or 
oxybuprocaine 0.4% (novesine 0.4%, OmniVision, 
Munich, Germany) were administered into each eye. 
At 1 minute, rats received pentadecapeptide BPC 157 
(0.4 µg/eye), l-nAMe (0.1 mg/eye) and l-arginine 
(2 mg/eye), administered alone and in combination. 
The agents were administered locally (two drops/eye) 
(Sigma Aldrich, St. louis, uSA), while controls re-
ceived a respective saline volume.
Corneal sensitivity measurement
using the Cochet-Bonnet esthesiometer (luneau 
Ophtalmologie, Chartres, france), a corneal sensitivity 
measurement device24, corneal sensitivity was mea-
sured in rats administered 0.5% tetracaine or 0.4% 
oxybuprocaine before corneal anesthesia, then after 
tetracaine or oxybuprocaine application, before thera-
py application, at 1 min, and with therapy application, 
at 5-minute intervals until full sensitivity was restored.
Briefly, the Cochet-Bonnet esthesiometer consists 
of nylon monofilament that can be pulled out and pro-
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duces a pressure force at its top, which is inversely pro-
portional to the length of the elongated portion of the 
monofilament. The nylon filament is 0.12 mm in di-
ameter and is 6 cm long. Corneal sensitivity testing 
started with gentle touch of the fully extended tip of 
the esthesiometer perpendicular to the cornea and ap-
plying a small force to finely distort the filament. if the 
rat blinked, it was recorded as a positive response. if 
the blinking response was absent, filament length was 
reduced by 1 centimeter and the procedure was repeat-
ed until a positive response was obtained. The absence 
of positive response when the filament length is 1 cen-
timeter is defined as complete block. The length of 
filament in centimeters that caused positive response 
was recorded. in the case of complete block, the value 
0 was recorded. As mentioned, after initial corneal 
sensitivity testing, each eye was tested at 5-min inter-
vals until full sensitivity was restored.
Corneal epithelium defect assessment
in rats administered 0.5% tetracaine that received 
saline or BPC 157, l-nAMe and/or l-arginine eye 
drops as described above, corneal epithelium defects 
considering long-term exposure were assessed at 30, 
60 and 150 minutes of the experiment. Corneal epi-
thelium defects were monitored by slit lamp (PSl 
Portable Slit lamp, reichert, Buffalo, uSA) with blue 
cobalt filter and by photographing the lesions after 
staining with standard 10% fluorescein (Alcon, Gene-
va, Switzerland), according to the experimental proto-
col. The test was positive if there was an epithelial de-
fect and negative if there was no epithelial defect. 
Scoring is performed by assessing the area affected 
with corneal defects divided in quarters, from no de-
fects (0/4) to the whole area of the cornea being af-
fected with epithelium defects (4/4).
Schirmer test assessment
Schirmer test was performed at 30, 60 and 120 min 
in 0.5% tetracaine rats that received saline or BPC 
157, l-nAMe and/or l-arginine eye drops as de-
scribed above30. Standard Schirmer tracks using 2-mm 
wide test strips cut from Schirmer test paper to fit the 
size of the rat eye were inserted 1 mm into the inferior 
conjunctival fornix and placed for 5 minutes, after 
which results in millimeters were recorded (the values 
of 5.5±1.0 mm obtained in healthy rats were consid-
ered normal).
Table 1. 0.5% tetracaine induced corneal anesthesia in rats and effect of pentadecapeptide 
BPC 157 (0.4 µg/eye), L-NAME (0.1 mg/eye) and/or L-arginine (2 mg/eye) administered 
alone or in combination after complete corneal anesthesia was established, at 1 min  
after 0.5% tetracaine
Pentadecapeptide BPC 157 (0.4 µg/eye), l-nAMe  
(0.1 mg/eye), l-arginine (2 mg/eye), administered alone  
and in combination after complete corneal anesthesia was 
established, at 1 min after 0.5% tetracaine







BPC 157 45±4.6* 94±7.0*
l-arginine 51±8.5* 90±5.3*
l-arginine + BPC 157 34±5.8*# 72±5.8*#
l-nAMe 84±7.7* 126±8.4*
l-nAMe + BPC 157 65±7.1# 100±9.4#
l-arginine + l-nAMe 73±8.6*+ 123±8.2*+
l-arginine + l-nAMe + BPC 157 44±3.9*# 91±8.4*#
t1 = time point when blink response to maximal corneal stimulation appeared again; t4 = time point when 
corneal sensitivity returned to baseline values; t1-t4 = complete corneal anesthesia duration (minutes, mean 
± Sd); *p<0.05 vs. saline (control); #p<0.05 vs. corresponding ‘non-BPC 157 group’; +p<0.05 vs. correspond-
ing ‘l-nAMe-group’; Mann-Whitney test for independent samples followed by Benjamini and hochberg 
procedure to control the false discovery rate (fdr)
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Statistical analysis
data were processed by use of descriptive statistics 
according to their distribution (Kolmogorov-Smirnov 
test for normal distribution). The duration of complete 
corneal anesthesia (t1) and time interval until corneal 
sensitivity returned to baseline values (t4) for two dif-
ferent local anesthetic drugs (tetracaine and oxybupro-
caine) in regard to different adjuvants (saline, BPC, 
l-arginine, l-nAMe, and their combinations) were 
explored by the analysis of variance (AnOVA). differ-
ences in the effect of individual adjuvants and their 
combination on the duration of tetracaine/oxybupro-
caine induced corneal anesthesia were analyzed in de-
tail using the Mann-Whitney test for independent 
samples, followed by Benjamini and hochberg proce-
dure to control false discovery rate (fdr). All statisti-
cal analyses were performed using MedCalc 9.5.1.0 
(MedCalc Software, Mariakerke, Belgium). The values 
of p<0.05 were considered statistically significant.
Results
We focused on therapy relation between the stable 
gastric pentadecapeptide BPC 157, l-nAMe and l-
arginine, applied alone and/or in combination, and 
corneal anesthesia in rats (tables 1-3, figs. 1-4).
Corneal sensitivity measurement
A quite long-lasting corneal insensitivity was in-
duced by 0.5% tetracaine or 0.4% oxybuprocaine in 
each eye and measured using the Cochet-Bonnet es-
thesiometer (tables 1-2, figs. 1-2). At 1 minute after 
two drops of 0.5% tetracaine or 0.4% oxybuprocaine in 
each eye, rats received locally (two drops/eye) pen-
tadecapeptide BPC 157, l-nAMe, l-arginine, ad-
ministered alone and in combination. BPC 157 ap-
plied as eye drops consistently recovered corneal sensi-
tivity in both tetracaine- and oxybuprocaine-rats. in 
tetracaine-rats and oxybuprocaine-rats, an indicative 
point was that the full counteracting effect of the BPC 
157 administration also occurred in the presence of 
nOS-blockade (l-nAMe+BPC 157), as well as in 
nOS-substrate application (l-arginine+BPC 157). 
l-arginine eventually shortened the duration of cor-
neal insensitivity. lengthening of corneal insensitivity 
appeared after l-nAMe. When l-nAMe and l-
arginine were given together (l-nAMe+l-arginine), 
they antagonized each other’s effect (i.e. nOS specific 
Table 2. 0.4% oxybuprocaine induced corneal anesthesia in rats and effect of pentadecapeptide 
BPC 157 (0.4 µg/eye), L-NAME (0.1 mg/eye) and/or L-arginine (2 mg/eye) administered 
alone and in combination after complete corneal anesthesia was established, at 1 min  
after 0.4% oxybuprocaine
Pentadecapeptide BPC 157 (0.4 µg/eye), l-nAMe  
(0.1 mg/eye), l-arginine (2 mg/eye), administered  
alone and in combination after complete corneal 
anesthesia was established, at 1 min after 0.4% 
oxybuprocaine corneal anesthesia
duration of 0.4% oxybuprocaine 
corneal anesthesia
t1 (min),  
mean ± Sd
t4 (min),  
mean ± Sd
Saline 64±5.7 126±3.9
BPC 157 51±5.0* 106±7.4*
l-arginine 56±6.9* 112±5.9*
l-arginine + BPC 157 48±5.9*# 96±5.5*#
l-nAMe 89±5.7* 137±7.9*
l-nAMe + BPC 157 71±7.6# 104±7.0*#
l-arginine + l-nAMe 77±6.7*+ 131±8.0
l-arginine + l-nAMe + BPC 157 60±7.2# 98±6.7*#
t1 = time point when blink response to maximal corneal stimulation appeared again; t4 = time point when 
corneal sensitivity returned to baseline values; t1-t4 = complete corneal anesthesia duration (minutes, mean 
± Sd); *p<0.05 vs. saline (control); #p<0.05 vs. corresponding ‘non-BPC 157 group’; +p<0.05 vs. correspond-
ing ‘l-nAMe-group’; Mann-Whitney test for independent samples followed by Benjamini and hochberg 
procedure to control the false discovery rate (fdr)
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effect), but these rats still exhibited lengthening of cor-
neal insensitivity. Additional BPC 157 co-application 
(l-nAMe+l-arginine+BPC 157) would have re-es-
tablished counteraction over topical ophthalmic anes-
thetic-induced corneal insensitivity.
Corneal epithelium defect assessment
A quite long-lasting 0.5% tetracaine corneal insen-
sitivity was soon associated with development of cor-
neal lesions, sustained consistently until the end of the 
experiment, which was markedly influenced by pen-
tadecapeptide BPC 157, l-nAMe and l-arginine 
administered alone and in combination (figs. 3-4). 
Much like corneal insensitivity, BPC 157 applied as 
eye drops consistently reduced development of corneal 
lesions. likewise, the full counteracting effect of the 
BPC 157 administration also occurred in the presence 
of nOS-blockade (l-nAMe+BPC 157), as well as in 
nOS-substrate application (l-arginine+BPC 157). 
l-arginine that markedly shortened the duration of 
corneal insensitivity had only temporary effect on cor-
neal lesions, unable to counteract final lesions. Consis-
tent lengthening of corneal insensitivity with l-
nAMe was associated with initial protection reversed 
to subsequent aggravation. When l-nAMe and l-
arginine were given together (l-nAMe+l-arginine), 
their mutual antagonizing ensured that these rats, 
which exhibited lengthening of corneal insensitivity, 
consistently had fewer lesions. Additional BPC 157 
co-application (l-nAMe+l-arginine+BPC 157) re-
sulted consistently in fewer lesions.
Schirmer test assessment
Schirmer test showed that tetracaine application 
consistently decreased tear volume (table 3). BPC 157 
application completely counteracted tetracaine-in-
duced decrease of tear volume and maintained normal 
healthy values. l-arginine counteracted tetracaine-in-
duced decrease of tear volume only at the earliest in-
terval. l-nAMe initially counteracted but later even 
augmented tetracaine-induced decrease of tear vol-
ume. When given together, l-nAMe+l-arginine, 
they consistently counteracted tetracaine-induced de-
crease of tear volume. Additional BPC 157 co-appli-
cation (l-nAMe+BPC 157, l-arginine+BPC 157, 
l-nAMe+l-arginine+BPC 157) consistently coun-
teracted tetracaine-induced decrease of tear volume.
Discussion
With the investigated topical ophthalmic anes-
thetics applied on the surface of the eye and known to 
act by blocking sodium channels in neuronal axons, 
thus preventing conduction along the axons and keep-
ing the brain from detecting painful stimuli26, BPC 
157 applied as eye drops has a particular counteracting 
Table 3. 0.5% tetracaine corneal anesthesia in rats and effect of pentadecapeptide BPC 157 (0.4 µg/eye), L-NAME 
(0.1 mg/eye) and/or L-arginine (2 mg/eye) administered alone and in combination after complete corneal anesthesia 
was established, at 1 min after 0.5% tetracaine
Pentadecapeptide BPC 157 (0.4 µg/eye), l-nAMe (0.1 mg/eye), 
l-arginine (2 mg/eye) administered alone and in combination after 
complete corneal anesthesia was established, at 1 min after 0.5% tetracaine
At 30 min At 60 min At 150 min
Saline 2.5±0.5 2.0±0.6 2.0±0.6
BPC 157 6.5±0.5* 5.0±0.6* 5.5±0.5*
l-arginine 5.5±0.5* 3.5±0.5* 3.0±0.9
l-arginine + BPC 157 5.5±0.5* 6.0±0.6* 6.0±0.6*
l-nAMe 3.5±0.5* 2.5±0.5 1.0±0.6*
l-nAMe + BPC 157 4.0±0.6* 4.5±0.5* 5.5±0.5*
l-arginine + l-nAMe 4.0±0.6* 4.0±0.9* 5.0±0.9*
l-arginine + l-nAMe + BPC 157 4.5±0.8* 4.5±0.5* 5.5±0.5*
Standard Schirmer tracks using 2 mm-wide test strips cut from Schirmer test paper to fit the size of the rat’s eye were inserted 1 mm into 
the inferior conjunctival fornix and placed for 5 minutes after which results in millimeters (mean ± Sd) were read; *p<0.05 vs. saline (con-
trol); Mann-Whitney test for independent samples followed by Benjamini and hochberg procedure to control false discovery rate (fdr)
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Fig. 1. Complete course of 0.5% tetracaine corneal anesthesia in rats and effect of pentadecapeptide 
BPC 157 (0.4 µg/eye), L-NAME (0.1 mg/eye) and/or L-arginine (2 mg/eye) administered 
alone and in combination after complete corneal anesthesia was established, at 1 min after 0.5% 
tetracaine. After initial corneal sensitivity testing, each eye was tested at 5-minute intervals until 
full sensitivity was restored; *p<0.05 vs. saline (control).
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Fig. 2. Complete course of 0.4% oxybuprocaine corneal anesthesia in rats and effect of 
pentadecapeptide BPC 157 (0.4 µg/eye), L-NAME (0.1 mg/eye) and/or L-arginine (2 mg/eye) 
administered alone and in combination after complete corneal anesthesia was established, at 1 
min after 0.4% oxybuprocaine corneal anesthesia. After initial corneal sensitivity testing, each eye 
was tested at 5-minute intervals until full sensitivity was restored; *p<0.05 vs. saline (control).
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action. it recovers corneal sensitivity, markedly elimi-
nates corneal lesions, and counteracts decrease of tear 
volume by interacting with nOS. likely, this particu-
lar action may be consequential to the interference 
with the essential action of local anesthetics.
Of note, we should appreciate the BPC 157 actions 
responsible for healing of the perforating corneal in-
jury and total debridement of corneal epithelium and 
maintained corneal transparency, or BPC 157 coun-
teraction of the damaging effects of lacrimal gland ex-
tirpation and dry eye syndrome in rats20-22. These ac-
tions against topical ophthalmic anesthetics may be 
sustained, thus preventing the otherwise inescapable 
direct epithelial toxicity that would lead to corneal 
drying due to the loss of corneal sensation, causing 
subsequent decrease in blink rate and tear production.
Thus, we recorded lesion counteraction and even-
tually less lesion formation in both tetracaine-rats and 
oxybuprocaine-rats administered BPC 157 therapy. in 
addition, BPC 157 markedly interferes with atropine 
effects, reduces atropine-induced mydriasis, and there-
by it may increase tear volume once it has been de-
creased with the application of topical ophthalmic an-
esthetics on the surface of the eye.
As mentioned above, BPC 157 largely interacts 
with nOS in different models and species, with both 
l-nAMe and l-arginine effects1-13. in tetracaine-rats 
and oxybuprocaine-rats, an indicative point is that the 
full counteracting effect of BPC 157 administration 
also occurs in the presence of nOS blockade (l-
nAMe+BPC 157) and nOS substrate application 
(l-arginine+BPC 157). Moreover, it occurs in the cir-
cumstances of particular nOS involvement. While 
both antagonize atropine-induced mydriasis23, after 
topical ophthalmic anesthetics l-nAMe and l-argi-
nine they have a distinctive effect on corneal insensi-
tivity duration, rate of corneal lesions and tear volume. 
Fig. 3. Corneal epithelium defects, scored 0-4  
(Min/Med/Max), course with 0.5% tetracaine corneal 
anesthesia in rats and effect of pentadecapeptide BPC 157 
(0.4 µg/eye), L-NAME (0.1 mg/eye) and/or L-arginine 
(2 mg/eye) administered alone and in combination after 
complete corneal anesthesia was established, at 1 min after 
0.5% tetracaine corneal anesthesia. After initial corneal 
sensitivity testing, each eye was tested at 5-minute 
intervals until full sensitivity was restored; *p<0.05  
vs. saline (control).
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l-arginine eventually shortens duration of corneal in-
sensitivity, shows counteraction to corneal lesions (and 
counteraction of tetracaine-induced decrease in tear 
volume), however, only in the early but not in later pe-
riod. l-nAMe application was associated with pro-
longed corneal insensitivity, higher rate of corneal le-
sions and reduction of tear volume. When l-nAMe 
and l-arginine were given together (l-nAMe+l-
arginine), they antagonized each other’s effect (i.e. 
nOS specific effect), and these rats exhibited length-
ening of corneal insensitivity, but had less corneal le-
sions. They also counteracted tetracaine-induced de-
crease of tear volume. Thus, with corneal insensitivity, 
l-nAMe effect prevailed over l-arginine effect; with 
less corneal lesions, l-arginine effect prevailed over l-
nAMe effect. This distinctive effect (corneal insensi-
tivity, corneal lesion, tear formation) may indicate par-
ticular nOS involvement (corneal insensitivity vs. 
corneal lesion along with tear formation) that may be 
distinctively affected by the application of nO agents. 
Anyway, be it in the early or late course, additional 
BPC 157 co-application (l-nAMe+l-arginine+BPC 
157) would have re-established counteraction over 
topical ophthalmic anesthetic-induced effects (i.e. par-
ticular BPC 157 to nOS relations).
Of note, distinctive nOS presentation was also re-
corded in other studies with various models23,31-34. This 
provides a common model23,31-34 that supports particu-
lar nOS involvement also beyond the topical ophthal-
mic anesthetic-induced adverse effects. On the other 
hand, this combined point observed with BPC 157 
administration implicates its particular relations with 
topical ophthalmic anesthetics and possible counter-
action of their adverse effects. unlike topical ophthal-
mic anesthetic inhibition, with the open eye, there are 
light-evoked increases in tear volume35, thus BPC 157 
can permanently (l-arginine only temporarily) evoke 
protective reflexes such as lacrimation.
The noted counteraction of severe cardiac distur-
bances (bradycardia, prolongation of all of the ob-
served waves and intervals, AV-block, ventricular ec-
topy, ventricular tachycardia, t-wave elevation and 
asystole) after bupivacaine (and counteraction of other 
various arrhythmias)14-19 appears much like counterac-
tion of adverse effects of tetracaine and oxybuprocaine 
topical ophthalmic anesthetics applied on the surface 
of the eye. Greater bupivacaine potential of direct car-
diac toxicity than other agents, greater affinity for in-
active and resting sodium channel configurations and 
slower dissociation from these channels36 together 
support an even more effective counteraction of all tet-
racaine- and oxybuprocaine-induced adverse effects, as 
recorded in our study. Moreover, these findings ap-
proach the BPC 157 counteracting effect on the es-
sential chain of the events following local anesthetic 
application36,37. These may be essential for penetration 
of both the epineurium and neuronal membrane, du-
ration of the action by the time that local anesthetic 
remains in close proximity to neural fibers, and tetra-
caine lipid solubility and neuronal protein binding re-
sulting in a local anesthetic that is more potent with an 
extended duration of action38.
Of note, in corneal innervation studies39-41, me-
chanical threshold assessed by Belmonte esthesiome-
ter provides structural and functional correlation, and 
thus corneal nerve function maintenance and recovery. 
in systemic terms, this may explain why BPC 157 pro-
duced analgesia in the MgSO4 and acetic acid intra-
peritoneal test29, and counteracted peritonitis in sev-
eral models31-33,42.
likewise, in rats with severed sciatic nerve, BPC 
157 markedly improves nerve healing and counteracts 
autotomy43 that reflects chronic neuropathic pain, neu-
roma at the proximal nerve stump, regenerative nerve 
sprouts growing into all directions, as prevents or, at 
Fig. 4. Illustrative presentation of the course of corneal 
defects with 0.5% tetracaine corneal anesthesia in BPC 157 
treated rats (upper) and control rats (lower), at 30 (left),  
60 (middle) and 150 (right) minutes after 0.5% tetracaine. 
Corneal epithelium defects were monitored by slit lamp 
(PSL Portable Slit Lamp, Reichert, Buffalo, USA) with 
blue cobalt filter and by photographing the lesions after 
staining with standard 10% fluorescein (Alcon, Geneva, 
Switzerland) according to the experimental protocol.
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least, significantly attenuates the chain of events oth-
erwise leading to the painful sensation referred to as 
denervated region44. A corresponding autotomy coun-
teraction appears in l2-l3 spinal compression model 
when the stable gastric pentadecapeptide BPC 157 
improves the healing course of the spinal cord injury 
and leads to functional recovery in rats45. As men-
tioned above, much like topical ophthalmic anesthet-
ic-induced adverse effects, BPC 157 counteracts mor-
phine-induced analgesia46 and counteracts nSAid-
induced toxicity7,47-55, also known to decrease corneal 
sensitivity56. Therefore, the stable gastric pentadeca-
peptide BPC 157 can be a quite distinctive ‘healing 
antidote’ for adverse effects of topical ophthalmic an-
esthetics.
Considering the combined vasoconstrictive and lo-
cal anesthetic properties, BPC 157 may also have a 
particular effect on vasculature that may influence the 
duration of topical ophthalmic anesthetic effect. This 
may be rapid activation of the bypassing loop that oc-
curs in the rat with infrarenal occlusion of the inferior 
vena cava (and thereby, resolved Virchow), much like 
in the rats with ischemic/reperfusion colitis, duodenal 
venous congestion lesions, perforated cecum, bile duct 
ligation induced liver cirrhosis and portal hyperten-
sion31-33,42,57. Accordingly, BPC 157 interacts with sev-
eral molecular pathways1,42,58-64. in particular, BPC 157 
increased expression and internalization of VeGfr2, 
activation of the VeGfr2-Akt-enOS signaling 
pathway without the need of other known ligands or 
shear stress61.
finally, to counteract topical ophthalmic anesthet-
ic-induced disturbances, it may be that BPC 157 has 
an effect of its own on membrane potential. inhibition 
of depolarization of heK293 cells by bupivacaine in 
vitro fully supports that BPC 157 may, through direct 
action, successfully counteract the effect of topical 
ophthalmic anesthetics, much like the effect of bupiva-
caine14.
likewise, cell depolarization due to increasing 
magnesium concentration was inhibited in the pres-
ence of BPC 157 (1 µM) in vitro34. furthermore, BPC 
157 reduced depolarization caused by hyperkalemia in 
heK293 cells15. depolarization caused by BPC 157 
(1 µm) was inhibited by the application of the nonspe-
cific potassium blocker BaCl2 (1 mM)15. in conclu-
sion, we suggest BPC 157 as an antidote of topical 
ophthalmic anesthetics.
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Sažetak
PentAdeKAPePtid BPC 157 SKrAĆuJe trAJAnJe AneSteZiJe rOŽniCe  
iZAZVAne tetrAKAinOM i OKSiBuPrOKAinOM KOd ŠtAKOrA
I. Mirković, T. Kralj, M. Lozić, V. Stambolija, J. Kovačević, L. Vrdoljak, M. Zlatar, K. Milanović, D. Drmić,  
J. Predović, S. Masnec, M. Jurjević, M. Bušić, S. Seiwerth, A. Kokot i P. Sikirić
u ovom istraživanju ispitivali smo međuodnos anestezije rožnice uzrokovane 0,5% tetrakainom odnosno 0,4% oksi-
buprokainom i pentadekapeptida BPC 157 (0,4 µg/oko) u kombinaciji s inhibitorom nitrid oksida l-nAMe (0,1 mg/oko) 
i/ili supstratom nitrid oksida l-argininom (2 mg/oko) primijenjenim u obliku kapi za oči. Procjenjivali smo anesteziju rož-
nice (Cochet-Bonnetov esteziometar), nestajanje lezija rožnice (bojenje 10% fluoresceinom) te volumen nastajanja suza 
(Schirmerov test). učinak potpunog poništavanja anestezije rožnice uočen je u skupinama koje su primale BPC 157. Opora-
vak je također nastupio u skupinama koje su primale i supstrat i blokator nitrid oksida. l-arginin skraćuje vrijeme neosjetlji-
vosti rožnice, a uočeno je i smanjenje lezija rožnice te poništavanje smanjenja lučenja suza, ali samo u ranijem kraćem raz-
doblju, dok se kasnije taj učinak gubi. l-nAMe je uzrokovao produženje vremena neosjetljivosti rožnice kao i povećanje 
lezija rožnice te dodatno smanjenje stvaranja suza. Kada se l-arginin i l-nAMe daju zajedno njihov učinak se poništava. 
Opažene razlike mogu ukazivati na određeni utjecaj i uključenost nitrid oksida (neosjetljivost rožnice naspram nastajanja 
lezija rožnice i stvaranja suza), što je pokazano primjenom supstrata/blokatora nitrid oksida. Međutim, u bilo kojoj kombi-
naciji prije ili kasnije, dodatak BPC 157 doveo bi do poništavanja učinka primijenjenih anestetika.
Ključne riječi: BPC 157; Tetrakain; Oksibuprokain; Anestezija rožnice; NOS; Štakori
